Financial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community

- Finalists will present their ideas during a live pitch event

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

- Astellas named Working Mother "100 Best Company" for fifth consecutive year -

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)

- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-

Glinski to Oversee US Sales for XTANDI

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -

- Data Presented at the American Urological Association 2019 Annual Meeting -

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -

- Companies Plan to Submit Biologics License Application Later This Year -

- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making

Data to be presented at the 2019 Genitourinary Cancers Symposium

Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline

- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -

Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic

Astellas ranked in recognition of its commitment and support for working mothers

Astellas recognized by Great Place to Work® Institute

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)

Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs

--Additional marketing award received for Best Video/TV Campaign--